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The involvement of connective-tissue-type mast cells
and chymase, a protease unique to their secretory
granules, has been implicated in ®brotic diseases. To
elucidate the role of chymase in ®broproliferative
in¯ammation, in this study we examined the enzy-
matic activity and mRNA expression of chymase in
the sclerotic skin of tight-skin mice; syngeneic Pallid
mice served as the control. Dorsal skin specimens
from mice aged 5, 10, and 20wk were evaluated by
morphometric and biochemical analyses. At ages 10
and 20wk, the hydroxyproline concentration in
tight-skin dermis was higher than that in Pallid. At
any age, the subcutaneous ®brous layer was thicker
in tight-skin than in Pallid. In accordance with these
®brous changes, both connective-tissue-type mast
cell counts and chymase activity were higher in
tight-skin skin than in Pallid skin up to 20wk of age.
Age-matched (10-wk-old) tight-skin and Pallid were
quanti®ed for their mRNA of connective-tissue-type
mast-cell-speci®c chymase, mouse mast cell pro-
tease-4, by the competitive reverse transcriptase
polymerase chain reaction technique, which revealed
its higher level in tight-skin than Pallid. In contrast,
the mRNA level of mouse mast cell protease-5, the
chymase isoform of undifferentiated mast cells, in
tight-skin skin was only a tenth that of mouse mast
cell protease-4 and no different from the mouse mast
cell protease-5 mRNA level of Pallid mice. An in situ
hybridization study con®rmed the higher expression
of mouse mast cell protease-4 by connective-tissue-
type mast cells in tight-skin skin than Pallid skin.
These results strongly support the contention that
the connective-tissue-type mast cell chymase plays a
crucial role in ®broproliferative remodeling of the
skin. Key words: competitive RT-PCR/in situ hybridiza-
tion/mouse mast cell protease-4/tight-skin mouse. J Invest
Dermatol 116:118±123, 2001
S
cleroderma is a multisystem disorder that is characterized
by massive deposition of collagen and other extracellular
matrix proteins in the skin and other organs. Although
the pathogenesis of scleroderma remains to be further
elucidated, the disease process involves immunologic
mechanisms, vascular damage, and activation of ®broblasts (Gilli-
land, 1998). In early scleroderma, mast cell counts in the involved
skin are increased (Nishioka et al, 1987) together with other
immune cells including CD4+ helper T cells (Gilliland, 1998).
Additionally, there have been numerous lines of circumstantial
evidence that suggest the involvement of mast cells in the
development of scleroderma (Claman, 1989, 1993). Indeed,
Seibold et al (1990) indicated that activation and proliferation of
mast cells preceded clinical ®brosis. Moreover, reciprocal interac-
tions between mast cells and ®broblasts are well known: stimulation
of mast cell proliferation, differentiation, and maturation by
®broblasts and vice versa (Levi-Schaffer, 1995). On the basis of
these observations, mast cells have been postulated to play a major
role in the etiopathology of scleroderma (Levi-Schaffer, 1995).
When considering the potential mast cell role in scleroderma, it
should be kept in mind that the subset of mast cells that are
increased in number and in an activated state in the involved tissue
is mostly the connective-tissue-type mast cell (CTMC) subset as
judged from its granular ultrastructure and positive staining for
heparin (Claman, 1993). In general, mature mast cells are classi®ed
into two subsets: CTMCs and mucosal mast cells (MMCs).
Although derived from the common pluripotent hematopoietic
stem cells, these two mast cell subsets are different in their
localization, morphology, and physiology (Denburg, 1995). In
humans, CTMCs synthesize and store two types of serine proteases
in their secretory granules: tryptase (EC 3.4.21.59) and chymase
(EC 3.4.21.39). Thus, human CTMCs are usually called MCTC.
On the other hand, human mucosal mast cells express tryptase
alone and hence this subset is usually called MCT (Schwartz, 1989).
Because it is not the MCT subset but the MCTC subset that is
increased in number and is likely to be involved in scleroderma as
stated above (Claman, 1993), it seems reasonable to postulate that
the chymase that is exclusively expressed by MCTC may play a
unique and critical role in the development of scleroderma and
other ®brotic disorders. This is the principal hypothesis of our
study.
To examine our hypothesis, we employed a genetic mouse
model of human scleroderma, the tight-skin (Tsk) mice (Green et al,
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1976; Menton et al, 1978; Kasturi et al, 1994). By using this mouse
and comparing with the syngeneic Pallid mouse as a standard, in
our study we examined whether the mast cell counts, chymase
mRNA, and chymase activity are increased in association with the
development of skin ®brosis in Tsk mice. An important concern
about the study is that mice, unlike humans, have more than one
chymase isoform, the respective functions of which have not yet
been identi®ed (Springman and Sera®n, 1995). Fortunately,
however, mouse chymase-4 (usually called mouse mast cell
protease-4, mMCP-4) is speci®cally expressed by mature CTMCs
(Springman and Sera®n, 1995). Similarly, mMCP-2 is speci®c to
mature mucosal mast cells, whereas mMCP-5 is abundantly
expressed by bone-marrow-derived mast cells (BMMCs) that are
rather immature and have a potential to differentiate to mature mast
cells depending on the combination of cytokines in the milieu
where progenitor mast cells are located (Ghildyal et al, 1992; Xia
et al, 1996). Therefore, mMCP-4 can be regarded as the functional
equivalent to human chymase. Accordingly, in this study we
examined whether gene expression and enzyme activity of mMCP-
4, but not of mMCP-2 or mMCP-5, are speci®cally exaggerated in
accordance with the age-related development of skin ®brosis in Tsk
mice.
MATERIALS AND METHODS
Animal preparation and tissue sampling Tight-skin (Tsk; C57BL/6-
Tsk+/+pa) mice and syngeneic (Pallid; C57BL/6-+pa/+pa) mice were
originally obtained from the Jackson Laboratory (Bar Harbor, ME). A Tsk
colony has been maintained at the Institute of Experimental Animals,
Shimane Medical University, by brother-sister matings of C57BL/6-Tsk+/
+pa males with C57BL/6-+pa/+pa females. The back skin of male Tsk
mice at ages 5, 10, and 20 wk was harvested under pentobarbital anesthesia
(40 mg per kg bodyweight, intraperitoneal), and skin biopsy specimens
from the region were obtained (n = 6 at each age). The Pallid mutant served
as a control (n = 6 at each age).
Specimens taken from the interscapular region at each age were ®xed in
neutral-buffered formalin for 72 h. Sections (5 mm thick) were embedded in
paraf®n and stained with hematoxylin and eosin, Azan, or toluidine blue.
Chymases were extracted and total RNA was isolated from the dorsal skin
as described later.
This study was conducted in accordance with the Guiding Principles for
the Care and Use of Laboratory Animals approved by the Committee of
Shimane Medical University.
Indices of ®brous proliferation in Tsk skin Morphologic
characteristics of skin sections from Tsk mice were compared with those
of Pallid mice under a light microscope. The thickness of the subcutaneous
®brous layer (see Fig 1) was measured in mice aged 5, 10, and 20 wk with a
two-dimensional image analysis system (Nikon Cosmozone 1SA, version 2;
Nikon, Tokyo, Japan) using Azan-stained sections. The widths of the
subcutaneous ®brous layer from 10 representative sites were averaged and
used as the index of ®brous proliferation.
Hydroxyproline is a unique constituent of collagen. The dermal
concentration of this amino acid was quanti®ed in mice aged 5, 10, and
20 wk to index collagen accumulation in dermis. In brief, the skin tissue
was hydrolyzed in 30 volumes (vol/wt) of 6 M HCl at 110°C for 22 h in
sealed glass tubes and then evaporated to dryness. The remaining
hydrolysates were neutralized with NaOH in vacuo overnight and dissolved
in 0.02 M HCl. Hydroxyproline was assayed using an amino acid auto-
analyzer (Model 853, Hitachi, Tokyo, Japan) on the basis of absorbance at
440 nm. Total amino acid concentration of the same samples was
determined by ninhydrin reaction and converted to total protein weight,
to which the amount of hydroxyproline was normalized (Bocchieri et al,
1993; Wang et al, 1999).
Measurements of mast cell density and chymase activity The
number of mast cells in dermis at the ages of 5, 10, and 20 wk was counted
on toluidine-blue-stained sections and calculated as the number per square
millimeter (excluding adnexas and hair follicles).
Chymase was extracted from dorsal skin at the ages of 5, 10, and 20 wk
and its activity was measured as described previously (Nishikori et al, 1998).
Brie¯y, skin specimens were minced and homogenized in 10 volumes (vol/
wt) of 20 mM sodium phosphate buffer (low ionic-strength buffer; pH 7.4)
using a motor-driven glass/glass Potter-type homogenizer to solubilize
readily soluble proteins and other soluble molecules. The homogenate was
then centrifuged at 20,000 3 g for 30 min and the supernatant was discarded
because it contained soluble proteins and other molecules that might
interfere with the in vitro determination of chymase activity. This step was
repeated twice so as to exhaustively remove the interfering substances. The
pellets were resuspended and homogenized in ®ve volumes (vol/wt) of
high ionic-strength buffer consisting of 10 mM sodium phosphate buffer
(pH 7.4), 2 M KCl, and 0.1% polyoxyethylene octylphenyl ether, a
nonionic detergent (Wako Pure Chemical Industries, Osaka, Japan). The
homogenate was agitated overnight at 4°C, and then centrifuged at
20,000 3 g for 30 min. The ®nal supernatant was used as the chymase
extract. Chymase activity (mU per mg protein) was estimated as the
hydrolysis rate of suc-Phe-Pro-Phe-p-nitroanilide (BACHEM
Feinchemikalen, Bubendorf, Switzerland) at 37°C. In the hydrolysis
reaction, p-nitroaniline is released as a yellow chromophore, the
absorbance of which was measured at 394 nm for 5 min with a spectro-
photometer (UV-1600; Shimadzu, Kyoto, Japan). The slope of the linear
increase in the absorbance (DA394 per min) was converted into chymase
activity. Aprotinin inhibits most serine-class protease activities except
chymase, whereas chymostatin completely inhibits chymase activity.
Therefore, the net chymase activity was de®ned by subtracting the
hydrolysis activity in the presence of both chymostatin and aprotinin from
that in the presence of aprotinin alone. Protein concentration in the ®nal
extract was measured with bicinchoninic acid (BCA) protein assay reagent
(Pierce Chemical, Rockford, IL).
Quantitative reverse transcriptase polymerase chain reaction (RT-
PCR) analysis Total RNA was isolated from the dorsal skin of 10-wk-
old mice according to the procedure established by Shiota et al (1992). One
microgram of total RNA was hybridized with 20 pmol random primer
(TaKaRa, Otsu, Japan) by heating at 72°C for 10 min. Reverse
transcription proceeded by incubating for 60 min at 37°C in 20 ml of
Tris-HCl (pH 8.3) containing 75 mM KCl, 10 mM dithiothreitol, 3 mM
MgCl2, 0.5 mM each deoxynucleotide, 20 units ribonuclease inhibitor
(Toyobo, Osaka, Japan), and 200 units Molony murine leukemia virus
reverse transcriptase (Gibco BRL, Gaithersburg, MD). Competitive RT-
PCR proceeded in 100 ml of PCR buffer containing 2 ml of reverse
transcriptase mixture, 25 pmol of sense and antisense primers for mMCP-4
or mMCP-5, 100 mM of each deoxynucleotide, 10 mM Tris-HCl (pH 8.3),
50 mM KCl, 1.5 mM MgCl2, 2.5 units Taq DNA polymerase (Boehringer
Mannheim, Mannheim, Germany), and 2-fold serial dilutions of mMCP-4
competitor DNA (8.4 3 102±1.1 3 105 molecules) or mMCP-5 competitor
DNA (4.2 3 102±5.4 3 104 molecules). To amplify mMCP-4, two
oligonucleotide primers were selected from the 5¢ and 3¢ regions of the
coding sequence (sense primer 5¢-ACC ACT GAG AGA GGG TTC ACA
GC-3¢, position 157±179; antisense primer 5¢-GAA GAC TCT GAT
GCA CGC AGG TC-3¢, position 810±788). Primers for mMCP-5 were
also selected from the 5¢ and 3¢ regions of the coding sequence (sense
primer 5¢-CTG AGA ACT ACC TGT CGG CCT GC-3¢, position 159±
181; antisense primer 5¢-TCC AGT TCC AGA TTT CCT CAC GG-3¢,
position 814±792) and primers for mMCP-2 were selected similarly (sense
primer 5¢-CCA CTA AGA ACG GTT CGA AGG AG-3¢, position 135±
157; antisense primer 5¢-GCT GGG ATG AAC TCA GAG GTA CC-3¢,
position 821±799). The competitor DNA for mMCP-4 was obtained by
deleting the 164 bp fragment using the restriction enzymes Aat I and Pst I.
The PCR products for target mMCP-4 and the competitor consisted of
654 and 490 bp, respectively. The competitor DNA for mMCP-5 was
obtained by deleting the 173 bp fragment using the restriction enzymes Sma
I and Acc I. The PCR products for target mMCP-5 and the competitor
consisted of 656 and 483 bp, respectively. The PCR was carried out on a
DNA thermal cycler (GeneAmp PCR system 9600, Perkin-Elmer,
Norwalk, CT). The ampli®cation conditions for mMCP-4 were 94°C
for 1 min, 63°C for 1 min, and 72°C for 1 min over 45 cycles; those for
mMCP-5 were 94°C for 1 min, 64°C for 1 min, and 72°C for 1 min over
45 cycles; and those for mMCP-2 were 94°C for 1 min, 60°C for 1 min,
and 72°C for 1 min over 43 cycles.
Eight microliters of PCR products were electrophoretically separated on
1.4% agarose gels, stained with ethidium bromide, and photographed. The
stained images were scanned with an image analyzer (Image-Pro Plus,
Media Cybernetics, Silver Spring, MD) and the integrated density of PCR
products of the target and competitor cDNAs was calculated using gel
analysis software (Gel-Pro Analyzer, Media Cybernetics). To correct the
difference in relative molecular mass between target and competitor cDNA
products, the integrated areas for mMCP-4 and mMCP-5 competitors
were multiplied by factors of 1.33 (654 bp/490 bp) and 1.36 (656 bp/
483 bp), respectively. The logarithm of the ratio (competitor PCR
product)/(target PCR product) was plotted versus the logarithm of the
amount of competitor DNA molecules. At the competition equivalent
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point (log ratio = 0), the original amount of chymase transcripts is supposed
to be equal to the amount of competitor DNA added to the initial reaction
mixture, and therefore can be calculated by extrapolating from the
intersection of the curves to the x axis (Shiota et al, 1998).
In situ hybridization of mMCP-4 Small pieces of skin were obtained
from the interscapular region of 10-wk-old Tsk and Pallid mice and
subjected to in situ hybridization for mMCP-4 mRNA as follows. Skin
samples were ®xed in 4% paraformaldehyde containing 0.5%
glutaraldehyde, 1 mM CaCl2, and 1 mM MgCl2 in 0.1 M sodium
phosphate buffer overnight, and then paraf®n sections were prepared.
After pretreatments with proteinase K (20 mg per ml), 4%
paraformaldehyde, 0.2 M HCl, and 0.1 M triethanolamine (TEA; pH 8.0),
the sections were acetylated with 0.25% acetic anhydride in 0.1 M TEA for
10 min, rinsed with 0.1 M phosphate buffer, dehydrated with a graded
series of ethanol solutions, and air-dried. Digoxigenin (DIG)-labeled
antisense RNA probes were prepared using the DIG RNA Labeling Kit
(Boehringer Mannheim) according to the manufacturer's instructions.
Clones of the PCR product subcloned into pBS II KS vector (Stratagene,
La Jolla, CA) were linearized with EcoR I and transcribed with T3 RNA
polymerase. A control sense RNA probe was generated by linearization
with Sal I and transcription with T7 RNA polymerase. The hybridization
solution consisted of 50% deionized formamide, 10% dextran sulfate,
1 3 Denhardt's solution, 10 mM Tris/HCl (pH 7.6), 1 mM ethylenediamine
tetraacetic acid, 0.25% sodium dodecyl sulfate, 0.6 M NaCl, 200 mg per ml
of tRNA, and approximately 0.5 mg per ml of sense or antisense RNA
probe. Sections were hybridized with the above mixture at 45°C for 16 h in
a moisture chamber, and then washed in 5 3 standard saline citrate (SSC) at
50°C for 10 min and 2 3 SSC containing 50% formamide at 50°C for
30 min. After digestion with RNase A (30 mg per ml) at 37°C for 30 min,
the sections were washed in 2 3 SSC at 50°C for 20 min and further
washed twice with 0.2 3 SSC at 50°C for 20 min. RNA signals were
visualized using a DIG Nucleic Acid Detection Kit (Boehringer
Mannheim). The sections were ®nally photographed and double-stained
with toluidine blue, which metachromatically stained the CTMC secretory
granules.
Statistical analysis All data are expressed as means 6 SEM. Statistical
analysis was performed using Student's t test when a single treatment group
was compared with a control group. Multiple comparisons were made by
analysis of variance followed by the post hoc Bonferroni/Dunn's test.
Difference was considered signi®cant for p < 0.05.
RESULTS
Fibrous proliferation of the skin in Tsk mice Skin tightness
of Tsk mice was manifested by dif®culties in gathering a fold of
skin, particularly in the interscapular area of the dorsal region.
Microscopy revealed dermal thickening and an increase in
subcutaneous loose connective tissue (subcutaneous ®brous layer)
beneath the panniculus carnosus muscle in Tsk mice (Fig 1b),
whereas these alterations were not seen in control Pallid mice
(Fig 1a).
At the age of 5 wk, there was no signi®cant difference in
hydroxyproline concentrations of the dorsal dermis between Tsk
and Pallid mice (Fig 2a). Although the concentration was increased
signi®cantly with aging from 5 to 10 wk old in the dorsal regions of
both Tsk and Pallid mice, the rate of increase was higher in Tsk
than in Pallid. The hydroxyproline concentration was signi®cantly
higher at 10 and 20 wk of age in the Tsk than in the Pallid mice.
The subcutaneous ®brous layer in the dorsal region became thicker
as Tsk mice aged (Fig 2b). Between 10 and 20 wk, this layer
became signi®cantly thicker in Tsk mice, contrasting with little
change in the Pallid mice. Additionally, the area of thickened
®brous layer in Tsk was signi®cantly broader than that of Pallid
mice at 5, 10, and 20 wk of age.
Mast cell density and chymase activity The mast cell number
in the Tsk dermis was signi®cantly larger and almost double that in
Pallid dermis at any age (Fig 3a). The mast cell number decreased
signi®cantly with age in Pallid dermis, whereas the decrease was
insigni®cant in Tsk. In addition, degranulating mast cells were
frequently found in toluidine-blue-stained sections of Tsk dermis
but not of Pallid dermis.
The net chymase activity in the dorsal skin of Tsk was obviously
higher than that of Pallid, and this higher activity in Tsk continued
up to 20 wk of age (Fig 3b). The activity in Tsk was approximately
2.5±8 times higher than that in Pallid. The level of chymase activity
rapidly decreased between 10 and 20 wk of age in Pallid skin, but
not in Tsk skin.
Competitive RT-PCR analysis and mRNA levels of mMCP-
4 and mMCP-5 Qualitative RT-PCR analysis showed that
mMCP-4 (CTMC-speci®c chymase) and mMCP-5 (BMMC-type
chymase) mRNAs, but not mMCP-2 (mucosal-mast-cell-speci®c
chymase) mRNA, were expressed in the mice skin (data not
shown). Therefore, mMCP-4 and mMCP-5 mRNA levels in the
skin layers of Pallid and Tsk mice were quantitatively analyzed by
competitive RT-PCR. Figure 4 shows an example of competitive
RT-PCR analysis that used constant amounts of reverse
transcriptase mixture and serially diluted concentrations of
mMCP-4 competitor cDNA. The RT-PCR ampli®cate (target)
from Tsk skin evidently competed with higher doses of competitor
than did that from Pallid mice skin. The logarithm of the ratio
Figure 1. Dermal thickening and an increase in subcutaneous loose
connective tissue (subcutaneous ®brous layer) in Tsk mice.
Histologic ®ndings of (a) control Pallid and (b) Tsk mouse skin (scale bar:
100 mm). The tissues were obtained from the interscapular region of mice at
the age of 20 wk.
Figure 2. Development of ®broproliferation in Tsk mouse skin. (a)
Hydroxyproline concentration in dermis and (b) thickness of the
subcutaneous ®brous layer of Pallid and Tsk mice (n = 6 each). Data are
shown as the mean 6 SEM. *p < 0.05 and **p < 0.01. ²p < 0.05 vs 5-wk-
old Pallid. ##p < 0.01 vs 5-wk-old Tsk. ³³p < 0.01 vs 5- or 10-wk-old
Tsk.
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(competitor PCR product)/(target PCR product) was plotted on
the y axis and the logarithm of the serial dilutions of the competitor
cDNA was plotted on the x axis for mMCP-4 (Fig 5a) and
mMCP-5 (Fig 5b), respectively. The relationship was linear
(r = 0.99, p < 0.001), which allowed accurate quanti®cation of the
target transcripts. The precise amount of target transcript was
determined by generating a standard curve for each sample tissue.
The mMCP-4 mRNA level in the Tsk mice skin was
substantially higher than that in the Pallid mice skin (Fig 6a).
Less mMCP-5 than mMCP-4 was expressed and the mMCP-5
mRNA level in Tsk mice did not signi®cantly differ from that in
Pallid (Fig 6b).
In situ hybridization of mMCP-4 To visualize higher
expression of mMCP-4 gene in the skin of Tsk than Pallid, in
situ hybridization was performed. mMCP-4 mRNA signal-positive
cells appeared dark-violet in both Pallid and Tsk dermis (Fig 7a, b).
The distribution density (positive cell number per unit area) and
staining intensity, however, were considerably higher in Tsk than
in Pallid dermis. mMCP-4 mRNA signal-positive cells were also
detected in the subcutaneous ®brous layer of Tsk skin (Fig 7c). The
wide distribution of the dark-violet stain and the characteristic
cellular morphology at high magni®cation (Fig 7d) together with
the fact that mMCP-4 mRNA signal-positive cells were also
stainable with toluidine blue (data not shown) con®rm the identity
of mRNA signal-positive cells as CTMCs. Speci®city of in situ
hybridization was con®rmed by the cells not staining dark-violet in
the presence of the control mMCP-4 sense RNA probe (data not
shown).
DISCUSSION
Our study revealed that the CTMC counts and chymase activity
were increased and the mRNA level of mMCP-4 (CTMC-speci®c
chymase) was speci®cally and remarkably elevated in Tsk skin
during ®brous proliferation. In contrast, mMCP-2 (mucosal-mast-
cell-speci®c isoform) mRNA was not detected at all in the skin
irrespective of diseased or normal condition. mMCP-5 (BMMC-
dominant isoform) mRNA was detected in the Tsk skin at one
tenth lower concentration than that of mMCP-4 and its level was
unchanged regardless of the progression of ®brosis. In view of the
more intense mMCP-4 mRNA signal on CTMCs in Tsk mice
than on those in control mice, as evident upon in situ hybridization,
the elevated level of mMCP-4 mRNA may indicate the augmented
gene expression for each CTMC rather than merely re¯ecting an
increase in mast cell number. These ®ndings, especially the
isoform-speci®c upregulation of mMCP-4 gene expression, have
strongly favored our hypothesis that the activated skin CTMC
chymase plays an important role in the development of ®brosis in
Tsk mice and presumably of human scleroderma.
We believe that this study is the ®rst to demonstrate the mast cell
subset-speci®c, isoform-selective upregulation of chymase in
Figure 3. Increases in mast cells and chymase in Tsk mouse skin. (a)
Number of mast cells in dermis and (b) net chymase activity in the skin of
Pallid and Tsk mice (n = 6 each). Data are shown as the mean 6 SEM.
**p < 0.01. ²p < 0.05 vs 5-wk-old Pallid. §§p < 0.01 vs 5- or 10-wk-old
Pallid.
Figure 4. Representative results from competitive RT-PCR ana-
lyses of skin mMCP-4 of Pallid and Tsk mice at the age of 10 wk.
Lane M contains j 3 174-HaeIII DNA marker. Lanes 1±6 contain PCR
products ampli®ed with 2 ml of reverse transcriptase reaction mixture and
2-fold serial dilutions of competitor DNA (1.1 3 105, 5.4 3 104, 2.7 3 104,
1.3 3 104, 6.7 3 103, 3.4 3 103 molecules).
Figure 5. Representative calibration plots of quantitative RT-PCR.
The logarithm of the ratio of competitor to target PCR products was
plotted versus the logarithm of the amount of competitor DNA molecules.
Quantitative RT-PCR analyses of skin for (a) mMCP-4 and (b) mMCP-5
mRNAs from Pallid and Tsk mice at the age of 10 wk. Each point shows
the average from three repetitive results.
Figure 6. High level of mMCP-4 mRNA in Tsk mouse skin. (a)
mMCP-4 transcripts and (b) mMCP-5 transcripts in the skin tissues of
Pallid and Tsk mice at the age of 10 wk (n = 6 each). Data are shown as the
mean 6 SEM. *p < 0.05 vs Pallid.
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sclerotic skin. Cellular and molecular mechanisms for speci®c
regulation of mMCP-4 gene expression remain to be clari®ed.
The Tsk mouse shows some similarities to human scleroderma
and some dissimilarities as well. Tsk mice provide an experimental
model of genetically linked ®brosis, and present a naturally
occurring scleroderma-like picture (Kasturi et al, 1994). In the
skin, heterozygous Tsk mice developed ®brosis involving dermis
and subcutaneous loose connective tissue (Green et al, 1976;
Jimenez and Christner, 1994). Demonstration of CD4+ helper T
cell involvement in skin ®brosis has indicated that the mechanism
of disease is immune-mediated injury as for human scleroderma
(Ong et al, 1999). The total number of mast cells in the cutaneous
tissue of Tsk mice was signi®cantly increased, suggesting that these
cells participate in the pathogenesis of scleroderma-like conditions
(Walker et al, 1985). Taken together, despite some dissimilarities
such that Tsk mice exhibit neither vascular pathology nor lung
®brosis (Gilliland, 1998; Ong et al, 1999), we consider that the Tsk
mouse should be an appropriate model for exploring the potential
role of mast cell chymase in scleroderma-like skin ®brosis.
Cautions should be kept in mind as to the species difference in
mast cell chymase isoforms, however. Humans have a single
chymase gene and express a single chymase isoform in the CTMC
(MCTC). In contrast, several chymase genes of mice have been
cloned at cDNA level. They are mMCP-1, mMCP-2, mMCP-4,
mMCP-5, and mMCP-9, although the functional signi®cance of
the respective chymases has not yet been identi®ed (Springman and
Sera®n, 1995; Hunt et al, 1997). Of these, the isoform that is
speci®cally expressed by CTMC is mMCP-4 (Huang et al, 1991;
Springman and Sera®n, 1995). In view of this, we consider
mMCP-4 as a functional equivalent to human CTMC chymase.
This is why we have investigated alterations in mMCP-4 mRNA
level in Tsk mice skin. In addition, we have measured, as
references, the mRNA levels of mMCP-5, which is an isoform
abundantly expressed by immature BMMCs, and of mMCP-2,
which is speci®c to mucosal mast cells (Ghildyal et al, 1992; Xia et al,
1996).
As already mentioned, this study has provided additional support
for our assumption that the CTMC chymase plays a critical role in
developing scleroderma and other ®brotic disorders. The mechan-
ism by which CTMC chymase promotes ®brosis, however, still
remains to be clari®ed. There is an accumulating body of in vitro
evidence that is relevant to chymase roles in the metabolism of
extracellular matrix proteins, although most of them are ®brolytic
rather than ®brogenic. For example, chymase degrades ®bronectins
and vitronectin by its direct catalytic action (Vartio et al, 1981). It
also degraded epidermal-dermal junction protein, which was yet
unidenti®ed (Briggaman et al, 1984). Chymase indirectly promotes
the cleavage of collagen and other extracellular matrix proteins by
processing matrix metalloproteinase (MMP) 1 (Lees et al, 1994;
Saarinen et al, 1994), MMP-3 (Lees et al, 1994), and MMP-9 (Fang
et al, 1997). On the other hand, chymase has been demonstrated to
directly process procollagen into collagen ®brils (Kofford et al,
1997). Moreover, chymase is supposed to indirectly induce
®broblast proliferation by liberating transforming growth factor
(TGF) b1, which is a potent pro®brotic cytokine from extracellular
matrix proteins (Border and Noble, 1994; Taipale et al, 1995), and
also by processing interleukin-1b (Mizutani et al, 1991) and
endothelin (Wypij et al, 1992; Nakano et al, 1997), which both are
strongly pro®brotic as well.
Angiotensin II is another well-known pro®brotic factor that is
generated by chymases of several species including humans. Indeed,
chymase is upregulated in in¯amed tissues in response to autoimmune
injury (hamster hereditary cardiomyopathy) and mechanical injury
(overstretched dog artery yielding intimal and adventitial ®brosis),
where upregulated chymase exaggerates angiotensin II formation,
thereby promoting ®brotic tissue remodeling (Shiota et al, 1993;
1997; 1998; 1999). Thus, it can be presumed that chymase-generated
angiotensin II is increased in human scleroderma tissues as well and
promotes ®brosis therein. It should be noted that the chymase roles in
®brosis may differ between humans and mice, however, because it is
unknown so far whether any mouse chymase isoforms generate
appreciable amounts of angiotensin II. Nevertheless, we believe that
mMCP-4 (the putative equivalent of human chymase in both
physiologic and anatomic respects) and human chymase might share a
number of pathogenic roles in ®brosis, e.g., processing of pro-MMPs,
TGF-b liberation, and many other roles that are independent of
angiotensin-II-mediated actions. Numerous studies are needed to
identify the true endogenous substrate(s) of chymase in ®brotic
diseases.
In addition to respective catalytic actions of chymase, interac-
tions between CTMCs and ®broblasts are noteworthy from the
aspect of ®brosis promotion (Levi-Schaffer, 1995). The micro-
environment established by ®broblasts is essential for proliferation,
differentiation, maturation, and viability of CTMCs. Mast cells, in
turn, induce migration and proliferation of ®broblasts, thereby
accelerating ®brosis (Levi-Schaffer and Kupietzky, 1990;
Sempowski et al, 1994; Levi-Schaffer, 1995). Although the
molecular mechanism by which mast cells activate ®broblasts is
insuf®ciently understood at the moment, chymase is a likely
candidate of effector molecule that activates ®broblasts.
Figure 7. In situ hybridization of mMCP-4.
(a) Dermis of Pallid mouse; (b) dermis of Tsk
mouse; (c) the subcutaneous ®brous layer of Tsk
mouse (scale bars: 50 mm); (d) high magni®cation
of an mMCP-4-positive cell. mMCP-4 mRNA
signal-positive cells appear dark-violet.
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From the above discussion, it is most likely that the chymase
liberated from CTMCs (chymase from human MCTC, and
mMCP-4 from mouse CTMC) may promote ®brosis as its overall
function even though chymase has the potential to accelerate both
®brolysis and ®brogenesis. This contention has been decisively
endorsed by our latest results. Daily treatment of Tsk mice with a
new synthetic inhibitor of chymase, SUN C82571 (SUNTORY,
Osaka, Japan), lowered chymase activity and mMCP-4 mRNA
level as well and also attenuated ®brous proliferation in Tsk skin.2
With the aid of such convincing results from the latest study, our
study has advocated our assumption that CTMC chymase may play
a key role in scleroderma and other chronic ®broproliferative
in¯ammatory diseases.
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